The Europe Biodefense Market is expected to witness market growth of 5.4% CAGR during the forecast period (2020-2026).
Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks.
Over the last few years, genetic engineering and biotechnology have seen massive technological advancements, which have offered innovative ways to address these deadly and naturally occurring viruses that can be re-designed to create additional harm. Also, there is the easy availability of these organisms, which makes biodefense a significant aspect for countries across the globe. To carry out bioterrorism, various biological agents have been used such as botulism, anthrax, and chemical & nuclear agents, causing severe destruction.
The biodefense market is still in the initial phase. The governments in emerging and developed countries are taking several initiatives that ensure the safety of the population. Various governments are proposing programs that include storing vaccines and biodefense machines used on account of a sudden bioterrorism attack.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
By Country
Companies Profiled
Unique Offerings from the Publisher
Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks.
Over the last few years, genetic engineering and biotechnology have seen massive technological advancements, which have offered innovative ways to address these deadly and naturally occurring viruses that can be re-designed to create additional harm. Also, there is the easy availability of these organisms, which makes biodefense a significant aspect for countries across the globe. To carry out bioterrorism, various biological agents have been used such as botulism, anthrax, and chemical & nuclear agents, causing severe destruction.
The biodefense market is still in the initial phase. The governments in emerging and developed countries are taking several initiatives that ensure the safety of the population. Various governments are proposing programs that include storing vaccines and biodefense machines used on account of a sudden bioterrorism attack.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/nuclear,
- Other Products
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Biodefense Market by Product
Chapter 5. Europe Biodefense Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Methodology
LOADING...